Quick Answer
Trevi Therapeutics, Inc. reported Net Income of -$42.76 million for fiscal year 2025.
Trevi Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$42.76M | +10.8% |
| 2024 | -$47.91M | -64.8% |
| 2023 | -$29.07M | +0.3% |
| 2022 | -$29.15M | +14.1% |
| 2021 | -$33.94M | -3.6% |
| 2020 | -$32.76M | -25.8% |
| 2019 | -$26.05M | -26.8% |
| 2018 | -$20.55M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$11.80M | +10.9% | +4.1% |
| June 30, 2025 | -$12.30M | +0.4% | -19.0% |
| March 31, 2025 | -$10.34M | +5.2% | +21.9% |
| September 30, 2024 | -$13.24M | -72.0% | -7.2% |
| June 30, 2024 | -$12.35M | -72.9% | -13.3% |
| March 31, 2024 | -$10.90M | -70.3% | -41.6% |
| September 30, 2023 | -$7.70M | +6.9% | -7.7% |
| June 30, 2023 | -$7.14M | +11.3% | -11.6% |
- Trevi Therapeutics, Inc. showed an increase of +10.8% in Net Income compared to the prior fiscal year.
- Over the 2018–2025 period, Trevi Therapeutics, Inc.’s net income has declined by 108.1% (from -$20.55 million to -$42.76 million).
- The most recent figure is from Trevi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: